- Home
- DXR vs CSBR Comparison
DXR vs CSBR Comparison
Compare DXR & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | CSBR |
|---|---|---|
| Founded | 1970 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.4M | 82.7M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DXR | CSBR |
|---|---|---|
| Price | $9.02 | $5.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.5K | ★ 8.6K |
| Earning Date | 02-27-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 161.11 |
| EPS | ★ N/A | N/A |
| Revenue | $1,446,345.00 | ★ $2,900,000.00 |
| Revenue This Year | $44,935.22 | $4.84 |
| Revenue Next Year | $74.79 | $11.51 |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.10 | $5.50 |
| 52 Week High | $14.76 | $9.63 |
Technical Indicators
Market Signals| Indicator | DXR | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 19.66 | 49.84 |
| Support Level | $8.45 | $5.50 |
| Resistance Level | $9.37 | $6.29 |
| Average True Range (ATR) | 0.49 | 0.25 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 7.53 | 43.48 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.